Blocking MEK helped T cells last longer in lab models

The research points to a tradeoff: reducing production of cancer-killing proteins may preserve immune cells, but could weaken their attack. Patient benefit remains unproven.

The research points to a tradeoff: reducing production of cancer-killing proteins may preserve immune cells, but could weaken their attack. Patient benefit remains unproven.
Blocking a signaling molecule called MEK helped cancer-fighting T cells multiply more while consuming less energy, researchers at Memorial Sloan Kettering Cancer Center found. In laboratory models, the cells also persisted under difficult conditions surrounding a tumor. The possible advantage comes with a tradeoff: slower production of the proteins that kill cancer cells.
ScienceDaily described the research, published in the journal Immunity, in an October 5 report. The animal and laboratory findings suggest that lowering the cells’ workload could help sustain an immune response. They do not establish that this approach improves cancer treatment outcomes in patients.
Cancer immunotherapy helps T cells, a type of immune cell, attack tumors. Checkpoint inhibitors are one form of this treatment: they remove biological restraints on T-cell activity. But sustained exposure to cancer can leave T cells unable to maintain their attack or control tumor growth—a condition called T-cell exhaustion.
The workload matters. T cells repeatedly encountering tumor antigens—cancer proteins recognized as foreign—must make cancer-killing, or cytotoxic, proteins. This can overburden their mitochondria, the structures inside cells that turn nutrients into usable energy. Santosha Vardhana, the physician-scientist whose laboratory conducted the research, says MEK regulates the decision to produce high levels of cytotoxic proteins.
The team found that exhausted T cells were highly active in their energy use, rather than sluggish. First author Tanmana Mitra described the problem as a mismatch between what the cells are asked to do and the energy they have available. The greater multiplication seen after MEK inhibition, alongside lower energy consumption, led the researchers to identify protein production as a major drain on the cells’ resources.
Reducing MEK signaling eased the pressure to keep making cytotoxic proteins, allowing some T cells to remain active and capable of renewing themselves for longer. Vardhana says the cells lived longer while producing cancer-killing proteins at a slower rate. A longer-lasting response could therefore come at the cost of a less intense attack.
Exhaustion is not always simply a failure to overcome. Earlier work by MSK immunologist Andrea Schietinger found that reduced activity can protect T cells from overstimulation and death. Excessive MEK activity, however, can push cells into terminal exhaustion: a severely depleted state in which immunotherapy can no longer reactivate them.
Analysis
Vardhana proposes that preserving T cells could matter more when tumors are large or tumor-fighting immune cells are scarce, because the immune response may not eliminate the cancer quickly. With small tumors and many attacking immune cells, he suggests that maintaining a strong, rapid response may be more useful than conserving the cells. These are proposed treatment scenarios, not established rules for choosing patients.
Vardhana says MEK inhibitors already approved by the US Food and Drug Administration could allow the approach to be tested in humans without much delay. Whether longer-lasting T cells would improve cancer control in patients—and when reduced attack intensity would be an acceptable tradeoff—remains unresolved.

The regulator found that codes did not make roughly one million patients’ records anonymous. IQVIA was also ordered to comply within 120 days.
2 min

Data from more than six million people reveal different patterns by age and region. Self-reports can also include people missed by estimates based on medical diagnoses.
3 min

Unusually large, below-freezing water drops can splash behind conventional ice protection. NASA’s tunnel tests aim to help engineers understand the hazard, with data analysis still under way.
2 min